The primary and definitive treatment of medullary thyroid cancer (MTC) is surgical resection. Recurrent or residual disease is typically a result of incomplete surgical removal.
M edullary thyroid cancers (MTCs) are derived from thyroid C-cells, named due to their calcitonin production, and account for 3% to 4% of thyroid cancers (1) . For patients with MTC localized to the neck, complete surgical resection remains the best therapeutic option (2) . These tumors are unresponsive to radioactive iodine therapy because they do not express the sodium-iodine symporter. External beam radiation is used for local control when surgery is no longer an option. Traditional chemotherapies are ineffective, and the Food and Drug Administration-approved multikinase inhibitors, vandetanib and cabozantinib, can result in high transient disease control rates but are not curative and are associated with toxicities (3, 4) .
Achieving optimal surgical outcomes requires removal of all target tissue and minimizing surgery time and risk to other tissues. To accomplish this, imaging prior to surgery is imperative. Current imaging modalities have made impressive progress, but each has limitations. Ultrasound (US), magnetic resonance imaging, and computed tomography can be effectively used to identify primary tumors and used to determine gross lymph node involvement. Positron emission tomography (PET) imaging using 18 F-dihydroxyphenylalanine-PET and 18 F-fluorodeoxyglucose-PET can identify between 35% and 45% of progressive MTC lesions (5) . Nuclear medicine g scintigraphy using 99m Tc sestamibi can also be used but has poor sensitivity and lacks specificity due to uptake in a variety of tissues (6) .
Complete removal depends on a surgeon's ability to differentiate normal from diseased tissue. Intraoperative assessment is largely based on surgeon experience and pathological frozen sectioning analysis (FSA) of tissue that has been removed, typically lymph nodes and surgical margins. FSA is also time intensive as the surgeon waits for sample preparation, hematoxylin and eosin (H&E) staining, and review by a pathologist (7) . The other significant limitation of FSA is that it does not evaluate tissue left in situ. The extent of tissue removed is based on the discretion of the surgeon. This limitation of pathologic tissue identification during surgery points to a need for better intraoperative methods of assessment. Intraoperative imaging has been successfully adapted in other cancer types (8, 9) . Fluorescence image-guided surgery using near-infrared (IR) fluorescent contrast agents has been shown to decrease residual tumor and improve survival in mouse models of melanoma and mammary adenocarcinomas (10) . Similarly, proof of concept for using fluorescence-guided resection in papillary thyroid cancer was established in a transgenic BRAF V600E murine model (11) . Tumor-specific imaging agents may improve patient outcomes if these agents can increase the accurate surgical removal of all malignant tissue (12) . An ideal molecule will be readily absorbed, nontoxic, available during the surgical procedure, and eliminated shortly after surgery. This molecule would need to be disease tissue specific with minimal uptake in normal tissues to reduce background activity (13) . The molecule should be available intraoperatively to be seen easily by the surgeon. Near-IR agents enable visualization of fluorescence by the surgeon, which is not otherwise visible to the naked eye, and contribute relatively low auto-fluorescence. IRdye800 provides better tissue penetrance and brightness than most other near-IR agents while having a low toxicity profile (14) , and thus was chosen as the label for our molecule.
A variety of near-IR fluorescent agents has been developed that allows the targeting of tumor cells in a specific manner (15, 16) . Although the purpose of these molecules has generally been drug delivery, their tumor specificity could also be exploited to enhance intraoperative imaging. Our initial studies were based on a compound known as HN-1, TSPLNIHNGQKL, which has previously been shown to be internalized and is cytotoxic to cancer cells when conjugated to a toxin or inhibitory peptide (17) (18) (19) . HN1 is a phage-derived peptide targeted initially to HNSCC cell lines. Its ability to internalize, requirement for micromolar concentrations, and fairly slow internalization (typically 24 hours) have been duplicated in other laboratories, and are suggestive of cell-penetrating peptides, although the mechanism is currently unknown (20) . Further development and labeling with IRDye-800 led to Compound-17 described in this work.
In this study, we describe the properties of the IRDye-800-labeled HN-1 analog, called Compound-17, in a biological context. We demonstrate that this peptide has high affinity for two MTC cells in vitro and in vivo. The binding dynamics suggest the molecule behaves as a cellpenetrating peptide, which may associate with mitochondria of MTC cells. Our studies in a murine flank xenograft model verified the in vitro results, albeit with background fluorescence. To examine imaging with this molecule in situ, we established an orthotopic xenograft model of MTC using techniques that have been previously successful for differentiated thyroid cancer orthotopic models (21) . This model allows us to examine localization of the imaging agent in a natural MTC setting by using existing vasculature and tumor microenvironment. It also decreases background fluorescence seen by our compound in the gastrointestinal and renal systems. We found that in both in vivo models of MTC (flank xenografts and orthotopic xenografts), the imaging peptide resulted in significant fluorescence at the site of the xenograft. We propose that this imaging molecule may have potential application to enhance surgical removal of MTC.
Materials and Methods

Conjugation of the IRDye-800
The labeled peptide was synthesized by standard solid state peptide synthesis. IRDye-800-NHS ester (Licor Biosciences, Lincoln, NE) was used to label the N-terminal monoprotected peptide in dimethyl sulfoxide and 4-methyl morpholine, using equimolar dye and peptide. The product was purified by reverse-phase C-18 high-performance liquid chromatography column to produce the desired monolysine-labeled product, which was lyophilized. The product had a single highperformance liquid chromatography peak on a C-18 column (.90% area by NIR800 emission detection of the dye).
Culture of cell lines
MZ-CRC1 cells were obtained from R. Gagel (MD Anderson, Houston, TX). TT cells were obtained from B. Nelkin (Johns Hopkins University, Baltimore, MD). All cells were verified mycoplasma free by PCR. All cells were verified to be of thyroid origin by short tandem repeat profiling (22) . Twenty thousand cells were plated on clear-bottom/black-plate 96-well (Corning Costar; 3603), and allowed to attach for 24 hours at 37°C in RPMI 1640 supplemented with 20% heatinactivated serum (Gibco; Catalog 10437-028), 1% minimum essential medium nonessential amino acids (Gibco), and 1% L-glutamine (Gibco; Catalog 25030-164).
In vitro binding assay
Cells were rinsed with 13 phosphate-buffered saline (PBS) and incubated with media without supplemental fetal bovine serum for the remainder of the experiment. Cells were incubated for 2 hours in 10 mM Compound-17 at 37°C in a 5% CO 2 humidified incubator. Following incubation with Compound-17, cells were rinsed three times in 13 PBS, then lysed in M-PER (Thermo Scientific) supplemented with aprotinin (1 mg/mL), leupeptin (1mg/mL), pepstatin (1mg/mL), 20 mM Amidinophenylmethanesulfonyl fluoride hydrochloride (APMSF), and 0.3 mM okadaic acid. Lysates were immediately examined on a Synergy H4 Hybrid Multimode Microplate Reader (BioTek).
Microscopy
A total of 6 3 10 4 cells was cultured on coverslips. Cells were carefully rinsed with 13 PBS and incubated in serum-free RPMI 1640 media with 10 mM Compound-17 and 200 mM MitoTracker Red CMXRos (Thermo Fisher Scientific). Cells were then incubated at 37°C in a humidified chamber for 1 hour. Stained cells were then rinsed in 13 PBS and incubated in serumfree RPMI 1640 media for 30 minutes. Cells were then rinsed with PBS and fixed with 4% formalin for 10 minutes and coverslips were mounted using Duolink II Mounting Medium with 4,6-diamidino-2-DAPI (Sigma-Aldrich, St. Louis, MO). All images were acquired at ambient temperature using an Olympus IX-81 microscope, with a 633 or 1003 Plan Apo oil immersion objective (1.4 numerical aperture), and a QCAM Retiga Exi FAST 1394 camera, and analyzed using the Slidebook software package (Intelligent Imaging Innovations, Denver, CO).
Subcutaneous xenografts
Cells were removed from the 10-cm 3 tissue culture dish by incubation with 0.25% trypsin EDTA (Gibco). Cells were rinsed in 13 PBS and resuspended at 1 3 10 7 cells/mL in 13 PBS. For each of two cell lines (TT and MZ-CRC1), one million cells of each cell line were then combined with 100 mL matrigel and injected into separate flanks (TT-right; MZ-CRC1 left) of athymic nude mice (5 weeks old, obtained from Target Validation Shared Resource at Ohio State University). Development of tumors was monitored by visual examination until volumes could be determined by caliper measurements. Tumor volumes were determined using the following formula: tumor volume = 1/2 3 [length 3 width (2)] (23). Once both tumors reached a minimum volume of 150 mm 3 , the animals were injected with 40 nmol Compound-17 via tail-vein injection. Animals were imaged using CRi Maestro at 3, 6, 24, 36, and 48 hours following the injection.
Near-IR fluorescence imaging
Forty-eight hours after injection, the animals were euthanized and skinned for imaging. The tumors along with internal organs were removed for imaging. The animals were imaged using both a CRi Maestro white light excitation imager (CRi, Woburn, MA) and a laser excitation FluobeamTM 800 NIR imaging system (Fluoptics, Grenoble, France). Comparisons between tissues were made by placing all tissues relevant to the comparison in the same image to equalize exposure time.
MTC orthotopic xenograft
Cell preparations and injection protocol
Cells were treated with 0.25% trypsin EDTA to remove from culture dishes. Cells were rinsed and resuspended in 13 PBS at 5 3 10 7 cells/mL and kept on ice. Athymic nude mice (;5 to 6 weeks; Target Validation Shared Resource at Ohio State University) were anesthetized with isofluorane and skin sterilized by use of 4% chlorhexidine (Henry Schein Animal Health, Columbus, OH). A sterile field was established, and a vertical cervical incision was made. Visualization was achieved by use of a dissecting microscope. Strap muscles and submandibular glands were separated and reflected, respectively, using blunt dissection. Once trachea and thyroid were adequately visualized, and 10 mL cell suspension was injected into the target thyroid lobe using an insulin syringe needle (27 ga; Terumo, Somerset, NJ). Submandibular tissue was reapproximated, and the incision was closed by use of 6-0 absorbable surgical sutures. Mice were allowed to recover from anesthesia, returned to their cage, and supplied with analgesics (2 mg/mL ibuprofen) for 7 days. All animal studies were done under protocols approved by Ohio State University Laboratory Animals Recourse.
US monitoring
Animals were examined weekly, starting the second week after injection, using a VisualSonics Vevo2100 system (Toronto, Canada). Mice were anesthetized as described previously. Threedimensional images were obtained by use of a three-dimensional motor attachment. Aquasonic 100 gel (Parker Laboratories, Fairfield, NJ) and a MS-550D transducer were used to acquire images. The default Cardiac package was used for general imaging. Transducer probe was set at 32 Hz and 80% power. The two-dimensional gain was set at 20DB, with scan distance at 8 mm and scan size set at 0.05 mm. Volumes were calculated using the VeVo Laboratory suite.
Tissue collection
Following euthanasia, blood was collected for serum preparation. Tumors, along with heart, lungs, liver, kidneys, and gastrointestinal tract, were excised. Tumor(s) was measured by calipers to determine final volume using the following formula: (4/3) 3 p 3 (length/2) 3 (width/2) 3 (height/2).
Calcitonin
To obtain blood serum, blood-obtained posteuthanasia was allowed to clot for 15 minutes at room temperature and then centrifuged at 1000g for 10 minutes to separate serum from clotted blood. Serum was stored at 280°C for no more than(Guernsey, UK) at 405 nm and at 450 nm. Data were input into a spreadsheet program for analysis.
H&E and calcitonin staining
Tumors and tissues were fixed in 10% zinc formalin (Thermo Scientific) for 3 days and then paraffin embedded and sectioned (4 mm). H&E staining was performed by the Solid Tumor Pathology Core at Ohio State University, as described previously (24) . Calcitonin antibody was purchased from Abcam (Cambridge, MA), and staining was performed using a 1:400 dilution of the primary antibody.
Statistical analysis
Wilcoxon rank-sums test was used to compare calcitonin levels between age-matched noninjected mice and mice bearing a xenograft. Spearman correlation was calculated for calcitonin concentration and the volume at necropsy.
Compound-17 in orthotopic xenografts
A total of 40 nmol Compound-17 was injected into the animal via tail-vein injection. The animals were imaged using both a CRi Maestro white light excitation imager and a laser excitation FluobeamTM 800 NIR imaging system (Fluoptics, Grenoble, 
Results
In vitro characterization of Compound-17
MTC interaction
We examined the ability of Compound-17 to bind to two MTC cell lines in vitro. MTC cells were exposed to Compound-17 and were compared with both nontreated control cells and cells treated with a negative control (Compound-83a), which is a sequence-jumbled version of the amino acids in HN-1 and Compound-17. Both MTC cell lines exposed to Compound-17 showed fluorescence in a dose-dependent manner, so that increasing concentration of Compound-17 correlated with increased fluorescence intensity. In contrast, cells exposed to Compound83a had no detectable fluorescence [ Fig. 1(a) ]. TT cells were slightly better at binding/engaging/internalizing Compound-17 than MZ-CRC1 cells [ Fig. 1(a) ].
We examined the subcellular localization of Compound-17 in the MTC cells. MTC cells were incubated with Compound-17 and Mito-tracker. 
Characterization of Compound-17 in a MTC subcutaneous flank xenograft model
We examined the localization of Compound-17 in a subcutaneous flank xenograft model for both MTC cells. Tumors that were at least 150 mm 3 were used in the experiment. Compound-17 was distributed relatively equally throughout the body in the 3-and 6-hour images [ Fig. 2(a) ]. Beginning at 24 hours and through the end of the experiment (48 hours) revealed retention of the agent in the tumor xenografts compared with the rest of the body, leading to improved visualization of xenografts over time [ Fig. 2(a) ]. As observed in Fig. 2(a) , uptake is generalized in early time points, and increased signal-tobackground in the xenografts is observed at later time points. We made future observations using the 24-to 48-hour time points because of the better target-tobackground ratio. Both cell lines appear to be equally capable of concentrating Compound-17 within the corresponding xenograft [ Fig. 2(a) ].
To examine whether the compound was retained nonspecifically within other organs, at 48 hours the animals were euthanized and the internal organs from the animal were removed and examined ex vivo for fluorescence. We found increased fluorescence in the MTC 
Characterization of MTC orthotopic xenografts
To examine the concentration of Compound-17 in the thyroid microenvironment, we established orthotopic xenografts for both TT and MZ-CRC1 cell lines by injecting each cell line into the thyroid lobes of five (TT) or six (MZ-CRC1) animals. Xenografts were successfully established in all animals injected with the TT cell lines, and in five of six of the animals injected with the MZ-CRC1 cell line. Growth of the xenografts was followed weekly with three-dimensional US starting at the second week after injection. Orthotopic xenografts were detectable as early as 3 weeks as a small hypodense nodule in the injected thyroid lobe (data not shown). As the xenografts enlarged, they took on a round contour and remained hypodense compared with surrounding tissues. Larger tumors were observed to extend to the contralateral side of the neck posterior to the trachea and esophagus. There was little variability in growth between each orthotopic xenograft in animals injected with TT cells [ Fig. 3(a) ]. Some difference was observed in final volume of orthotopic xenografts as calculated by the US software and volumes determined by caliper measurements following necropsy in xenografts derived from MZ-CRC1 cells [ Fig. 3(c) ].
Ex vivo examination of MTC orthotopic xenografts
Orthotopic xenografts were allowed to grow for 9 weeks prior to necropsy. Photo documentation was obtained both in vivo and ex vivo en block with trachea with representative animals from each cell line shown in Fig. 3(e-h) . Growth of the tumors was noted to be either spherical or mildly lobulated and well encapsulated [ Fig. 3(e-h) ]. Invasion into surrounding tissues was not observed [ Fig. 3(e-h) ]. Mass effect on the trachea and thyroid was observed in some animals [ Fig. 3(e-h) ]. These tumors did not demonstrate high vascularity [ Fig. 4(a) ]. Final US were performed 3 days prior to necropsy.
Histological examination of MTC orthotopic xenografts
Tumors were sectioned and processed for histologic examination. In some orthotopic xenografts, as shown in Fig. 4(a) (166, 168, and 855 ), tumor cells were seen growing around thyroid follicles. A capsule of connective tissue is seen around the xenografts. It is unclear whether this connective tissue is a host reaction or derived from the thyroid capsule, accommodating the growth of the tumor. Vasculature is seen coursing through the surrounding connective tissue, but the xenograft does not appear very vascular and no vascular invasion was observed. No metastasis to lymph nodes was observed, although tumors were removed en block with the trachea but not surrounding tissues, and consequently, lymph nodes were not present in sections used for histological analysis. Calcitonin staining was also performed, demonstrating expression of calcitonin in the orthotopic xenografts. Histology using calcitonin has confirmed that most of the component cells of the xenograft are derived from C-cells [ Fig. 4(a) ]. Although the colloid retains the secondary staining in the adjacent normal thyroid (where present), the follicular cells surrounding those follicles are negative for calcitonin immunoactivity [insets, Fig. 4(a) ]. Histologic examination was also performed in brain, lung, and liver stained. No metastasis to these organs was observed (data not shown).
Examination of serum calcitonin levels for MTC orthotopic xenograft-bearing mice
There was a significant increase in calcitonin levels of mice bearing MZ-CRC1 orthotopic xenografts (P value = 0.001536) and in mice bearing TT orthotopic xenografts https://academic.oup.com/jcem(P value = 0.001734) compared with age-matched controls [ Fig. 4(b) ]. We also examined the relationship between the tumor volume at necropsy and calcitonin concentration in the serum and found a moderate correlation between tumor volume and serum calcitonin concentration in MZ-CRC1 xenograft-bearing mice (Spearman = 0.57) and a strong correlation between xenograft volume and serum calcitonin concentration in TT xenograft-bearing mice (Spearman = 0.8) [Fig. 4(b) ].
Imaging of Compound-17 in a MTC orthotopic model We used the previously described orthotopic xenograft to examine the ability of Compound-17 to accumulate at the site of the orthotopic xenograft. Using the fluorescently labeled Compound-17, we determined that the compound concentrated in the orthotopic xenograft following tail-vein injection, although there was some variability between the different mice in part related to the size of the xenograft (Fig. 5) . Importantly, surrounding tissue did not fluoresce, indicating that Compound-17 specifically is internalized/binds to tumor cell-derived xenografts. Mice injected with sequencejumbled control (Compound-83a) did not have specific (or indeed, any detectable) fluorescence (Fig. 5) .
Discussion
We report the biological evaluation of a near-IR imaging molecule in MTC. Our initial experiments show that this molecule can bind and/or be internalized in two MTC cell lines using an in vitro assay. Microscopic evaluation using the same assay, along with the relatively high concentration needed for rapid internalization, suggests that the molecule behaves as a cell-penetrating peptide (11, 20, 25) . We examined cellular localization of Compound-17 in MTC cells using fluorescence microscopy and found that fluorescence in treated cells coincided with localization of mitochondria. This localization may be due to internalization at that location or to localization of a fluorescent metabolite at that location. The negative control compound (83a) demonstrated virtually no fluorescence in vitro, indicating specificity of Compound-17. The mechanism by which Compound-17 binds to and enters the cells is presently unknown. Hong and Clayman (15) described a peptide called HN1, which they found to be concentrated in squamous cancer cells most likely via receptor-mediated endocytosis, but that mechanism was not fully characterized. Compound-17 is partially derived from the same amino acids and may have a similar entry mechanism, but is far more rapidly taken up (H. Ding, et al., unpublished observation). Other cell-penetrating peptides are internalized through interactions with integrins (26) . Considering the apparent localization of Compound-17 to the mitochondria, there are a number of mitochondrial substances that may be important for its retention in the cell. For example, LyP-1, a cell-penetrating peptide previously described, is bound by p32, a mitochondrial chaperone protein that is responsible for oxidative phosphorylation (27) (28) (29) . In cells with very high metabolic activity, such as cancer cells, p32 is expressed at the cell membrane and not in the mitochondria, like in normal tissues.
We also observed specific fluorescence in flank xenografts in vivo [ Fig. 2(a) ] and ex vivo [ Fig. 2(b) ] that demonstrated excellent signal-to-background ratio over the time examined and renal excretion. Interestingly, the agent appears to diffuse equally and extensively through the entire tumor with different retention rates. The agent does not appear to be retained in or near the blood vessels or lymphatics. This could potentially lead to a more complete visualization of all tumor tissues, and not just the highly vascularized area of the tumor, although this requires further studies to confirm.
To better evaluate the practicality of Compound-17 in an intraoperative setting, we developed an orthotopic model of MTC in mice. Xenografts were established by direct injection into the thyroid bed during survival surgery, as previously described for various thyroid cancer cell lines (30) (31) (32) (33) . This allowed xenograft growth and development in a microenvironment that includes surrounding thyroid follicular cells, vasculature, and paracrine signaling. We confirmed the orthotopic location of the xenografts by murine neck US, which provides a noninvasive method similar to that used in humans. Alternative monitoring systems typically use bioluminescence, which requires genetically altered cells. MTC cell lines are slow growing, and the process of introducing a luciferase gene may have detrimental effects, including the selection of subclones. Because of tumor heterogeneity and the nuance of using US, there may have been some animals that had incomplete US imaging of their tumors, and, as a result in those cases, the total volume of the tumors on three-dimensional US underestimates the actual disease burden. Although there is a learning curve in using US for this application, it is a valuable tool that allows use of unlabeled cell lines and is noninvasive. Overall, we found that growth curves are smooth and consistent among animals, and that the volume of the tumors as recorded at final US closely approximates the volumes as measured during necropsy. Whereas reports of papillary thyroid carcinoma and anaplastic thyroid carcinoma orthotopic xenografts suggest large xenografts (100 to 200 mm 3 ) in 4 to 5 weeks (33), MTC orthotopic tumors achieved those large volumes between 9 and 10 weeks, correlating with their slow growth in vitro. Another helpful adjunct in evaluating tumor growth in the MTC orthotopic model is the measurement of serum calcitonin via enzyme-linked immunosorbent assay. Calcitonin is a useful biomarker in humans with MTC (34) . In animals with MTC xenografts, we found increased calcitonin concentrations compared with age-and sex-matched control animals. Although this was not applicable to the evaluation of Compound-17 in these animals, this served as a proof of concept that calcitonin was produced by the tumors and could potentially be used as a biomarker for pharmacodynamics measure of drug activity or response to therapy.
The use of Compound-17 in the MTC orthotopic model demonstrates its potential application in surgical resection. The tumors demonstrate intense fluorescence compared with surrounding tissues. There is minor background fluorescence in the surrounding muscle, trachea, and esophagus. In patients with widespread locoregional disease as well as in patients with locoregional recurrence in the operative setting, this level of resolution would prove valuable in differentiating scar tissue from active disease. This level of differentiation may be even more valuable in sensitive regions such as around the recurrent laryngeal nerve and other cranial nerves during lateral neck dissection. The ability to discriminate between malignant and nonmalignant tissue in real time without the need for biopsy is the ultimate goal to minimize risk to the patient and to obtain a more complete resection. Although Compound-17 is an excellent candidate, further studies are necessary to move it forward for use in humans as well as to maximize its potential in other applications. This includes evaluating its breadth of sensitivity and specificity, mechanism of action, pharmacodynamics and pharmacokinetics, and tolerability. Determining the optimal timing of administration of the compound prior to imaging is needed to maximize the signal-to-background ratio. Although there is appreciable work to be done, Compound-17 appears to have the potential for a significant impact for patients with MTC.
